About Us

About Us

Immunovant is a biopharmaceutical company committed to developing innovative therapies that not only treat the symptoms, but modify the course of autoimmune diseases.

Our primary investigational product candidate is IMVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases.

IMVT-1401 has completed a single and multiple ascending dose Phase 1 clinical trial in healthy volunteers and is presently in Phase 2a clinical development for the treatments of both myasthenia gravis and Graves’ ophthalmopathy. We also seek to continue expanding our pipeline, ultimately transforming the lives of patients who suffer from autoimmune diseases.